SCHEDULE: Treace Medical Concepts: CEO's Stake Detailed

John T. Treace reports beneficial ownership of 19.2% of Treace Medical Concepts' common stock as of June 30, 2026.

Summary

• John T. Treace, the CEO, has filed an updated Schedule 13G detailing his beneficial ownership of Treace Medical Concepts, Inc. common stock.
• As of June 30, 2026, Treace beneficially owns 12,530,959 shares, representing 19.2% of the outstanding common stock.
• This ownership includes shares held directly, by a family trust where he is trustee, by his spouse, by a family trust where his spouse is co-trustee, and by a family trust where he is co-trustee.
• The total also incorporates 401,175 shares underlying stock options exercisable within 60 days of the reporting date.
• The filing is an amendment (Amendment No. 4) to a previous Schedule 13G filing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting significant beneficial ownership by a key executive, indicating strong alignment with company performance.

Positives

• Significant beneficial ownership (19.2%) by the CEO, John T. Treace, indicating strong alignment with shareholder interests.
• The CEO holds direct voting and dispositive power over 9,045,893 shares.
• Additional shared voting and dispositive power over 3,485,066 shares.
• The filing confirms the total number of outstanding shares as of June 30, 2026, was 64,976,624.

Negatives

• No explicit negative financial or operational information is presented in this ownership disclosure filing.

Risks

• Concentration of ownership in a single individual could pose governance risks if not balanced by independent oversight.
• The value of the CEO's stake is directly tied to the company's stock performance, creating potential for personal financial pressure influencing corporate decisions.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or financial guidance.

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant insider ownership, particularly by the CEO, is common in the medical device sector, often signaling strong management conviction in the company's prospects. However, it also necessitates robust independent board oversight.

Comparison to Industry Standards

• Industry benchmarks for CEO ownership vary significantly by company stage and sector. For a company like Treace Medical Concepts, a 19.2% stake by the CEO is substantial compared to many publicly traded companies, where CEO ownership might range from less than 1% to over 10%.

Related Party Transactions

• The filing details shares held by family trusts and the CEO's spouse, which are considered related party holdings for beneficial ownership purposes.

Stakeholder Impact

• Shareholders: The significant CEO ownership can be viewed positively as it aligns management's interests with theirs, potentially driving long-term value creation.

Next Steps

• Continued monitoring of John T. Treace's beneficial ownership and any future amendments to Schedule 13G.

Key Dates

Keywords

beneficial ownership, Schedule 13G, insider trading, executive compensation, stock options, corporate governance, shareholder value, medical devices